ARCHIVES

J&J To Eliminate Its Ortho Biotech Unit As FDA Considers Further Limits On ESAs.

This article is from The Cancer Letter archive.

Vol. 34 No. 17 | May 2, 2008

Download PDF Visit The Full Archive

Related Articles

ACS Lists Challenges For Global Tobacco Control

January 22, 2010

Device Shortens Time To Make T Cells For Immunotherapy

March 27, 2009

Trifluridine and Tipiracil Hydrochloride Increase OS, PFS in Phase III Trial

July 25, 2014

Clinical Trials Approved By NCI During November Are Listed

December 27, 2002

Ohio State recruits neurosurgeon from Harvard to lead new department.

January 9, 2004

In Brief: Cancer Act Renewal Hearings Completed ; Administration Stays With Objections To More Centers, Specific Budget Figures

February 22, 1974